Skip to main content
. Author manuscript; available in PMC: 2022 Aug 10.
Published in final edited form as: J Am Coll Cardiol. 2021 Aug 10;78(6):625–631. doi: 10.1016/j.jacc.2021.06.010

FIGURE 3. Impact of Various Anticoagulants on Hemostasis Versus Thrombosis.

FIGURE 3

Current anticoagulants inhibit either FXa or thrombin (IIa) (DOACs), or both (heparins), or reduce synthesis of their precursors (VKAs). This will attenuate thrombosis but also compromise hemostasis. The greater role of FXI in thrombosis relative to hemostasis provides a potential target for hemostasis-sparing anticoagulation. Cross-sectional view of vessels shown with hemostasis in red and thrombosis in purple. DOACs = direct oral anticoagulants; VKA = vitamin K antagonist.